F-1/A: Psyence Biomedical Eyes Public Offering of 22.5 Million Shares and Warrants

Psyence Biomedical is seeking to register for resale 22,496,000 common shares and 570,000 warrants, along with the potential issuance of 13,070,000 common shares upon warrant exercise.

Summary

• Psyence Biomedical is registering for resale 22,496,000 common shares and 570,000 warrants.
• The registration includes the potential issuance of 13,070,000 common shares upon the exercise of outstanding warrants.
• The common shares are to be sold by selling securityholders, including investors from a convertible debt PIPE financing, and recipients of fee shares related to the Business Combination.
• The company will not receive any proceeds from the sale of shares by the selling securityholders, but will receive proceeds from any cash exercise of the warrants.
• The offering involves risks, including potential dilution and downward pressure on the market price of the common shares.
• The company is currently developing PEX010, a natural psilocybin medicinal formulation, for the treatment of adjustment disorder in patients with incurable cancer.
• A Phase IIb clinical trial is planned to assess the efficacy and safety of PEX010 in psilocybin-assisted psychotherapy.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there are positive aspects such as the clinical development program and licensing agreements, the company's financial losses, dependence on future funding, and potential dilution risks weigh heavily on the overall outlook.

Positives

• The company is progressing with its clinical development program for PEX010, with a Phase IIb clinical trial planned.
• The company has secured licensing agreements for PEX010, providing exclusivity for certain indications and territories.
• The company has a management team with experience in the pharmaceutical industry.
• The company is targeting a market with unmet medical needs, specifically adjustment disorder in palliative care.

Negatives

• The company has incurred significant losses since its inception and expects to incur losses for the foreseeable future.
• The company has never generated revenue and may never be profitable.
• The company will require substantial additional funding to achieve its business goals.
• The securities being offered represent vastly more than the number of outstanding Common Shares, and the sales of such securities could depress the market price of the Common Shares.
• The company received two letters from Nasdaq regarding minimum Market Value of Listed Securities and Market Value of Publicly Held Shares requirements.

Risks

• Sales of a substantial number of securities in the public market by the Selling Securityholders could cause the price of the Common Shares to fall.
• The market price and trading volume of the Common Shares may be volatile and could decline significantly following the Business Combination.
• The company is dependent on licensed intellectual property and may not be able to adequately protect or enforce its intellectual property rights.
• The company may infringe the intellectual property rights of others.
• The company may face difficulties enrolling patients in its clinical trials.
• The psychedelic therapy industry and market are relatively new and may not continue to exist or grow as anticipated.
• Negative public opinion and perception of the psychedelic industry could adversely impact the company's ability to operate and its growth strategy.
• The requirements of being a public company may strain the company's resources and divert management's attention.
• The company qualifies as a foreign private issuer and is exempt from certain provisions applicable to United States domestic public companies.
• The company currently reports financial results under IFRS, which differs in certain significant respects from U.S. GAAP.

Future Outlook

The company expects that the cash provided in the Business Combination and the PIPE Financing, assuming all tranches are consummated, together with the company's existing cash, will be sufficient to fund operations beyond 12 months following the Closing.

Industry Context

The announcement relates to the growing interest in psychedelic-assisted therapies, particularly for mental health conditions associated with serious illnesses. The company is positioning itself to be a first-mover in the palliative care and cancer-related AjD market.

Comparison to Industry Standards

• The document mentions Compass Pathways' clinical trial, which provides a benchmark for safety and efficacy in the psychedelic therapy space.
• The document references Filament Health Corp., a key player in the natural psilocybin production and extraction, highlighting the importance of supply chain and IP licensing in this industry.

Related Party Transactions

• The company issued an unsecured convertible promissory note to Parent in the principal amount of $1,610,657.
• NCAC issued an unsecured convertible promissory note to the Sponsor in the principal amount of $1,615,501.

Stakeholder Impact

• Shareholders may experience dilution and downward pressure on the market price of the common shares.
• The company's ability to execute its business plan and achieve profitability will impact the value of shareholders' investments.
• Patients with adjustment disorder may benefit from the development of PEX010 and psilocybin-assisted psychotherapy.

Next Steps

• Commence enrollment in the Phase IIb clinical trial in Australia in the second half of 2024.
• Seek input from the FDA with a pre-IND application.
• Potentially proceed to a Phase III trial in the United States, subject to FDA review and the opening of an IND.
• Actively monitor its MVLS and MVPHS and will evaluate available options to regain compliance with the Nasdaq continued listing standards.

Key Dates

Keywords

Psyence Biomedical, PEX010, clinical trials, psilocybin, adjustment disorder, palliative care, warrants, common shares, PIPE financing, business combination, registration statement